Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Dissecting Clinical Trial Data from the 81st Scientific Sessions
Diabetes & Dermatology: Uncovering Skin Conditions in Diabetic Patients
Investigating the Link Between Type 2 Diabetes & Obesity
Taking a New Approach to Treat Type 1 Diabetes
Improving Diabetes Care with Technology: A Look at Continuous Glucose Monitors
Discovering the Discordance Between Measured A1Cs & GMIs
Investigating SGLT-2 Inhibitors in Diabetes: Considerations & Conversation
A Wake-Up Call to Diabetes: Spreading Awareness of Its Seriousness
When & How to Screen Patients for Diabetes
Exploring Stem Cell Research & Novel Options in Type 1 Diabetes
Investigating Type 1 Diabetes & Its Chronic Impacts
Managing Diabetes During the COVID-19 Pandemic
Understanding Dapagliflozin: Examining Its Use in Chronic Kidney Disease
Assessing Atypical Diabetes: Detection & Diagnosis
Highlighting a Hero in Endocrinology: Dr. Jason Sloane
Fad Diets & Patients with Type 2 Diabetes
Cardio Considerations: Individualized Exercise for Patients with Type 2 Diabetes
Prescribing Exercise for Patients with Type 2 Diabetes
Dietary Decisions for Patients with Type 2 Diabetes
Difficulty with Diabetes: Strategies to Overcome Challenging Cases
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video